(0.05%) 5 310.69 points
(0.01%) 39 811 points
(0.00%) 16 795 points
(-0.74%) $79.21
(-2.54%) $2.68
(-0.56%) $2 424.80
(-1.21%) $32.04
(-0.20%) $1 061.60
(0.09%) $0.922
(-0.25%) $10.67
(0.00%) $0.787
(-0.40%) $90.32
-3.23% $ 2.70
Live Chart Being Loaded With Signals
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases...
Stats | |
---|---|
Volumen de hoy | 367.00 |
Volumen promedio | 2 467.00 |
Capitalización de mercado | 7.32M |
EPS | $0 ( 2024-05-14 ) |
Próxima fecha de ganancias | ( $0 ) 2024-07-26 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.500 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-04 | Chicko Rhonda M. | Sell | 0 | Common Stock |
2024-01-01 | Hecht Peter M | Buy | 15 000 | Common Stock |
2024-01-01 | Graul Regina Margaret | Buy | 50 000 | Common Stock |
2023-11-30 | Katabi Dina | Sell | 0 | Common Stock |
2023-11-30 | Higgins Michael J | Sell | 0 | Common Stock |
INSIDER POWER |
---|
100.00 |
Last 100 transactions |
Buy: 5 326 508 | Sell: 727 933 |
Cyclerion Therapeutics Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Cyclerion Therapeutics Finanzas
Annual | 2023 |
Ingresos: | $0 |
Beneficio Bruto: | $0 (0.00 %) |
EPS: | $-8.99 |
FY | 2023 |
Ingresos: | $0 |
Beneficio Bruto: | $0 (0.00 %) |
EPS: | $-8.99 |
FY | 2022 |
Ingresos: | $297 000 |
Beneficio Bruto: | $232 000 (78.11 %) |
EPS: | $-20.15 |
FY | 2021 |
Ingresos: | $3.94M |
Beneficio Bruto: | $3.94M (100.00 %) |
EPS: | $-1.193 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Cyclerion Therapeutics
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico